Cover Image
Market Research Report

North America Biochips Market Forecast 2019-2027

Published by Inkwood Research Product code 603657
Published Content info 92 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Biochips Market Forecast 2019-2027
Published: March 9, 2019 Content info: 92 Pages
Description

KEY FINDINGS

North America biochips market is expected to evolve with 20.89% CAGR over the forecast period of 2019-2027. Between these years, the market revenue is expected to increase from $xx million in 2018 and reach $x million by 2027. Biochips have a crucial requirement in molecular diagnostics, and their application in point-of-care diagnosis is expected to facilitate the development of personalized medicines.

MARKET INSIGHTS

Biochip has several applications in the field of medicine, biosciences, biotechnology, and molecular biology. In the medical industry, biochips are mostly used for drug discovery and for producing biomarkers. Investments by organizations like DARPA, NIH and the FDA to speed up the development of biochips in the U.S is acting as a major boosting factor for the market. Also, several key companies in this region are investing heavily in biochips technology.

On the other hand, venture capital funding by Turnstone Biologics to improve the R&D activities in the Canadian biotechnology sector, combined with the rising healthcare expenditure is expected to drive the growth across the Canada biochip market over the forecast period.

COMPETITIVE INSIGHTS

Noted companies in this market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Cybrdi Inc., Agilent Technology Inc., Cepheid Inc., IMGENEX, Biochain Institute Inc., Illumina Inc., Merck GmbH, Fluidigm Corporation, OriGene Technologies Inc., bioMerieux SA, Samsung Electronics Inc., PerkinElmer Inc. and Gamida for Life Group amongst others.

Table of Contents
Product Code: 12924

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY & FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. NORTH AMERICA DOMINATES THE OVERALL MARKET
    • 3.2.2. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF TYPE SEGMENT
    • 3.2.3. HOSPITALS & DIAGNOSTICS CENTERS - KEY END-USER VERTICAL
    • 3.2.4. PROTEIN CHIP TYPE IS PROJECTED TO RISE AT HIGHEST GROWTH RATE

4. MARKET DYNAMICS

  • 4.1. PARENT MARKET ANALYSIS: GENOMICS & PROTEOMICS MARKET
  • 4.2. ETYMOLOGY OF BIOCHIPS MARKET
  • 4.3. MARKET DEFINITION & SCOPE
  • 4.4. MARKET DRIVERS
    • 4.4.1. RISING INCIDENCES OF CANCER
    • 4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
    • 4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
    • 4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. LACK OF HEALTHCARE COVERAGE
    • 4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
    • 4.5.3. LACK OF AWARENESS AMONG COMMON PEOPLE ABOUT BIOCHIP TECHNOLOGY
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. TECHNOLOGICAL ADVANCEMENT IN THE BIOTECHNOLOGY
    • 4.6.2. GROWING APPLICATIONS OF BIOCHIPS
  • 4.7. MARKET CHALLENGES
    • 4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
    • 4.7.2. LACK OF COMMON REGULATORY STANDARDS
    • 4.7.3. HIGH INSTRUMENTATION COST

5. MARKET BY TYPE

  • 5.1. DNA CHIPS
    • 5.1.1. AGRICULTURAL BIOTECHNOLOGY
    • 5.1.2. CANCER DIAGNOSTICS & TREATMENT
    • 5.1.3. DRUG DISCOVERY
    • 5.1.4. GENE EXPRESSION
    • 5.1.5. GENOMICS
    • 5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
    • 5.1.7. OTHER DNA CHIPS APPLICATIONS
  • 5.2. LAB ON A CHIP
    • 5.2.1. CLINICAL DIAGNOSTICS
    • 5.2.2. DRUG DISCOVERY
    • 5.2.3. GENOMICS
    • 5.2.4. POINT OF CARE (POC) & IN-VITRO DIAGNOSIS (IVS)
    • 5.2.5. PROTEOMICS
    • 5.2.6. OTHER LAB ON A CHIP APPLICATIONS
  • 5.3. PROTEIN CHIPS
    • 5.3.1. DIAGNOSTICS
    • 5.3.2. DRUG DISCOVERY
    • 5.3.3. EXPRESSION PROFILING
    • 5.3.4. HIGH THROUGHPUT SCREENING
    • 5.3.5. PROTEOMICS
    • 5.3.6. OTHER PROTEIN CHIP APPLICATIONS
  • 5.4. OTHER CHIPS
    • 5.4.1. CELL ARRAYS
    • 5.4.2. TISSUE ARRAYS

6. MARKET BY SUBSTRATE MATERIALS

  • 6.1. GLASS
  • 6.2. POLYMERS
  • 6.3. SILICON
  • 6.4. OTHER SUBSTRATE MATERIALS

7. MARKET BY END-USERS

  • 7.1. BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
  • 7.2. HOSPITALS & DIAGNOSTICS CENTERS
  • 7.3. ACADEMIC & RESEARCH INSTITUTE

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE
    • 8.1.3. BARGAINING POWER OF SUPPLIERS
    • 8.1.4. BARGAINING POWER OF BUYERS
    • 8.1.5. THREAT OF COMPETITIVE RIVALRY
  • 8.2. OPPORTUNITY MATRIX
  • 8.3. VENDOR LANDSCAPE
  • 8.4. VALUE CHAIN ANALYSIS
    • 8.4.1. RESEARCH & DEVELOPMENT
    • 8.4.2. RAW MATERIALS
    • 8.4.3. MANUFACTURING
    • 8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
    • 8.4.5. END-USERS
  • 8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
  • 8.6. KEY BUYING CRITERIA
    • 8.6.1. COST
    • 8.6.2. APPLICATIONS
    • 8.6.3. PRODUCT TYPE
  • 8.7. INVESTMENT ANALYSIS
    • 8.7.1. BY END-USERS
    • 8.7.2. BY BIOCHIPS TYPE

9. GEOGRAPHICAL ANALYSIS - NORTH AMERICA

  • 9.1. UNITED STATES
  • 9.2. CANADA

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
  • 10.2. KEY COMPANY ANALYSIS
  • 10.3. CORPORATE STRATEGIES
    • 10.3.1. PARTNERSHIP & COLLABORATION
    • 10.3.2. MERGERS & ACQUISITIONS
  • 10.4. COMPANY PROFILES
    • 10.4.1. AGILENT TECHNOLOGY INC.
    • 10.4.2. BIOCHAIN INSTITUTE INC.
    • 10.4.3. BIOMERIEUX SA
    • 10.4.4. BIO-RAD LABORATORIES INC.
    • 10.4.5. CEPHEID INC.
    • 10.4.6. CYBRDI INC.
    • 10.4.7. FLUIDIGM CORPORATION
    • 10.4.8. GAMIDA FOR LIFE GROUP
    • 10.4.9. ILLUMINA INC.
    • 10.4.10. IMGENEX
    • 10.4.11. MERCK GMBH
    • 10.4.12. ORIGENE TECHNOLOGIES INC.
    • 10.4.13. PERKINELMER INC.
    • 10.4.14. SAMSUNG ELECTRONICS INC.
    • 10.4.15. THERMO FISHER SCIENTIFIC INC.

LIST OF TABLES

  • TABLE 1: NORTH AMERICA BIOCHIPS MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
  • TABLE 2: ESTIMATED NUMBER OF NEW CANCER CASES & ESTIMATED DEATHS DUE TO CANCER IN UNITED STATES IN 2017
  • TABLE 3: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
  • TABLE 4: ESTIMATED R&D EXPENDITURE IN MEDICAL & HEALTHCARE INDUSTRY OF UNITED STATES, 2013-2015 (IN $ MILLIONS)
  • TABLE 5: ESTIMATED R&D SPENDING IN BIOTECHNOLOGY, PHARMACEUTICAL, & MEDICAL INDUSTRY OF UNITED STATES, 2013-2015 (IN $ MILLIONS)
  • TABLE 6: NORTH AMERICA BIOCHIPS MARKET, BY TYPE, 2019-2027, (IN $ MILLION)
  • TABLE 7: NORTH AMERICA DNA CHIPS MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 8: NORTH AMERICA LAB ON A CHIP MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 9: NORTH AMERICA PROTEIN CHIPS MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA OTHER CHIPS MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 11: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
  • TABLE 12: NORTH AMERICA BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2019-2027 (IN $ MILLIONS)
  • TABLE 13: NORTH AMERICA BIOCHIPS MARKET, BY END-USERS, 2019-2027 (IN $ MILLIONS)
  • TABLE 14: OPPORTUNITY MATRIX
  • TABLE 15: VENDOR LANDSCAPE
  • TABLE 16: LEGAL, POLICY & REGULATORY FRAMEWORK
  • TABLE 17: NORTH AMERICA BIOCHIPS MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
  • TABLE 18: LIST OF PARTNERSHIP & COLLABORATION
  • TABLE 19: LIST OF MERGERS & ACQUISITIONS

LIST OF FIGURES

  • FIGURE 1: NORTH AMERICA BIOCHIPS MARKET, BY END-USER, 2018 & 2027 (IN %)
  • FIGURE 2: NORTH AMERICA BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 3: EVOLUTION & TRANSITION OF BIOCHIPS
  • FIGURE 4: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
  • FIGURE 5: UNITED STATES HEALTHCARE SPENDING, 2015-2025 (% OF GDP)
  • FIGURE 6: COMPARISON OF HEALTHCARE SPENDING PER CAPITA & OUT OF THE POCKET HEALTH EXPENDITURE
  • FIGURE 7: NORTH AMERICA BIOCHIPS MARKET, BY DNA CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 8: NORTH AMERICA DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2019-2027 (IN $ MILLION)
  • FIGURE 9: NORTH AMERICA DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2019-2027 (IN $ MILLION)
  • FIGURE 10: NORTH AMERICA DNA CHIPS MARKET, BY DRUG DISCOVERY, 2019-2027 (IN $ MILLION)
  • FIGURE 11: NORTH AMERICA DNA CHIPS MARKET, BY GENE EXPRESSION, 2019-2027 (IN $ MILLION)
  • FIGURE 12: NORTH AMERICA DNA CHIPS MARKET, BY GENOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 13: NORTH AMERICA DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2019-2027 (IN $ MILLION)
  • FIGURE 14: NORTH AMERICA DNA CHIPS MARKET, BY OTHER CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 15: NORTH AMERICA BIOCHIPS MARKET, BY LAB ON A CHIP, 2019-2027 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2019-2027 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2019-2027 (IN $ MILLION)
  • FIGURE 18: NORTH AMERICA LAB ON A CHIP MARKET, BY GENOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN-VITRO DIAGNOSIS (IVS), 2019-2027 (IN $ MILLION)
  • FIGURE 20: NORTH AMERICA LAB ON A CHIP MARKET, BY PROTEOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 21: NORTH AMERICA LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2019-2027 (IN $ MILLION)
  • FIGURE 22: NORTH AMERICA BIOCHIPS MARKET, BY PROTEIN CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 23: NORTH AMERICA PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2019-2027 (IN $ MILLION)
  • FIGURE 24: NORTH AMERICA PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2019-2027 (IN $ MILLION)
  • FIGURE 25: NORTH AMERICA PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2019-2027 (IN $ MILLION)
  • FIGURE 26: NORTH AMERICA PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 (IN $ MILLION)
  • FIGURE 27: NORTH AMERICA PROTEIN CHIPS MARKET, BY PROTEOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 28: NORTH AMERICA PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 29: NORTH AMERICA BIOCHIPS MARKET, BY OTHER CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 30: NORTH AMERICA OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2019-2027 (IN $ MILLION)
  • FIGURE 31: NORTH AMERICA OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2019-2027 (IN $ MILLION)
  • FIGURE 32: NORTH AMERICA BIOCHIPS MARKET, BY GLASS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 33: NORTH AMERICA BIOCHIPS MARKET, BY POLYMERS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 34: NORTH AMERICA BIOCHIPS MARKET, BY SILICON, 2019-2027 (IN $ MILLIONS)
  • FIGURE 35: NORTH AMERICA BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 36: NORTH AMERICA BIOCHIPS MARKET, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, 2019-2027 (IN $ MILLIONS)
  • FIGURE 37: NORTH AMERICA BIOCHIPS MARKET, BY HOSPITALS & DIAGNOSTICS CENTERS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 38: NORTH AMERICA BIOCHIPS MARKET, BY ACADEMIC & RESEARCH INSTITUTE, 2019-2027 (IN $ MILLIONS)
  • FIGURE 39: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 40: VALUE CHAIN ANALYSIS
  • FIGURE 41: KEY IMPACT ANALYSIS
  • FIGURE 42: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET IN 2018, BY END-USER
  • FIGURE 43: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET IN 2018, BY TYPE
  • FIGURE 44: NORTH AMERICA BIOCHIPS MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
  • FIGURE 45: UNITED STATES BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 46: CANADA BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 47: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2018 (IN %)
Back to Top